MET
Tejas Patil/X

Tejas Patil: MET and NF2 Alterations Linked to Primary Resistance in ALK TKI Therapy

Tejas Patil, Thoracic oncologist at University of Colorado Cancer Center, shared a post on X by Molecular Oncology

“Primary resistance is to ALK TKIs is a major clinical issue. Nearly 20% of pts in CROWN trial progressed within 6 months! This study in Molecular Oncology shows that MET and NF2 alterations may play a role in primary (early) ALK resistance.”

“MET and NF2 alterations confer primary and early resistance to first-line alectinib treatment in ALK-positive non-small-cell lung cancer.”

Authors: Jie Hu, Ning Ding, Xiaobo Xu, Yedan Chen, Yong Zhang, Jingwen Liu, Jiebai Zhou, Hairong Bao, Donghui Zhang, Yijun Song, Yang Shao, Yuanlin Song

Tejas Patil: MET and NF2 Alterations Linked to Primary Resistance in ALK TKI Therapy